Search

Savara Inc

Cerrado

SectorSanidad

4.73 -2.27

Resumen

Variación precio

24h

Actual

Mínimo

4.74

Máximo

5.01

Métricas clave

By Trading Economics

Ingresos

-2.9M

-40M

BPA

-0.16

Empleados

70

EBITDA

-2.9M

-40M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+131.4% upside

Dividendos

By Acuity

Próximas Ganancias

10 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-182M

992M

Apertura anterior

7

Cierre anterior

4.73

Savara Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 oct 2026, 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

12 oct 2026, 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

9 oct 2026, 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

8 oct 2026, 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

7 oct 2026, 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

6 oct 2026, 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

2 oct 2026, 20:01 UTC

Savara Inc shares fell sharply, experiencing significant volatility and trading below their 20-day moving average amid high market volume.

1 oct 2026, 19:46 UTC

Social Media

Savara Inc shares are trading lower as heightened short interest and increased volume coincide with the approach of its PDUFA date for molgramostim.

30 sept 2026, 21:03 UTC

Social Media

Savara Inc shares are trading higher in after-market hours amid speculation of a short squeeze ahead of its PDUFA date for molgramostim, with a market cap of $1 billion.

28 sept 2026, 20:02 UTC

Social Media

Savara Inc is trading higher amid notable social media activity and unusual options bets, with a PDUFA date set for November 22.

25 sept 2026, 20:07 UTC

Savara Inc shares fell sharply, continuing the downward trend with a cumulative return in negative territory and remaining below its 20-day moving average.

24 sept 2026, 19:46 UTC

Savara Inc is trading higher, having previously peaked before a slight retracement, though it remains below its 20-day moving average.

23 sept 2026, 22:01 UTC

Savara Inc gained in after-market trading following a brief decline earlier in the session, though it remains below its 20-day moving average.

22 sept 2026, 20:05 UTC

Savara Inc's stock is declining sharply, moving from an initial gain to a notable drop, trading below its 20-day moving average.

21 sept 2026, 20:12 UTC

Savara Inc is advancing in after-market trading, positioned above its 20-day moving average and near the upper end of its one-month range.

18 sept 2026, 23:11 UTC

Savara Inc is trading modestly higher in after-market hours, reflecting the broader market's upward movement, with notable gains since Friday's close.

17 sept 2026, 23:11 UTC

Savara Inc is seeing a modest upward move in after-market trading, currently near the upper end of its one-month range.

16 sept 2026, 20:10 UTC

Savara Inc shares fell sharply today, continuing a decline since Tuesday and trading significantly below its 20-day moving average.

15 sept 2026, 20:07 UTC

Savara Inc shares are lower, impacted by a sharp decline in the NY Empire State Manufacturing Index and rising oil prices amid broader market weakness.

11 sept 2026, 20:08 UTC

Savara Inc. shares are trading lower today, continuing a decline since Thursday's close amid a broader market downturn.

10 sept 2026, 20:03 UTC

Savara Inc. shares are lower today, reflecting broader market conditions amid the European Central Bank's recent interest rate hike and inflation projections.

4 sept 2026, 19:26 UTC

Savara Inc shares are higher today, trading within a narrow range. The stock is currently near the lower end of its one-month range.

3 sept 2026, 20:02 UTC

Savara Inc shares are lower during Thursday's session, retracing from an earlier peak amid rising jobless claims that may affect Federal Reserve policy.

2 sept 2026, 20:08 UTC

Savara Inc. shares are higher today, driven by a significant upward trend in the Biotechnology sub-sector. No specific company news was identified.

1 sept 2026, 19:36 UTC

Savara Inc. shares are lower today, continuing a decline since Monday. The stock remains below its 20-day moving average amid rising inflation concerns.

31 ago 2026, 22:01 UTC

Savara Inc. shares rose in after-market trading, advancing since Monday's close, despite earlier pulling back from a session high. No specific news was identified.

28 ago 2026, 21:02 UTC

In after-market trading, Savara Inc. has increased following a flat start, indicating upward momentum despite remaining below its 20-day moving average.

27 ago 2026, 23:56 UTC

Savara Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment remains mixed amid ongoing inflation concerns and upcoming Fed guidance.

25 ago 2026, 19:16 UTC

Event

Savara Inc announced presentations at the ERS Congress, yet shares are trading lower today, reflecting a slight decline since Monday's close.

24 ago 2026, 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

Comparación entre iguales

Cambio de precio

Savara Inc previsión

Precio Objetivo

By TipRanks

131.4% repunte

Estimación a 12 Meses

Media 11.2 USD  131.4%

Máximo 16 USD

Mínimo 9 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Savara Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat